Clinical trials: Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis, Atopic
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
- Trial name
- NCT07599813
- Testing
- Camoteskimab
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 280 people
- Sponsor
- Apollo Therapeutics Ltd
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Moderate-to-severe Atopic Dermatitis
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of subcutaneously CM310 in moderate-severe AD…
- Trial name
- NCT04893941
- Testing
- CM310
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse…
- Trial name
- NCT06552520
- Testing
- TQH2722 injection
- Where
- 73 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Atopic Dermatitis
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT05158023
- Testing
- ASLAN004
- Where
- 83 sites in United States, Australia and 6 more
- Volunteers
- 302 people
- Sponsor
- ASLAN Pharmaceuticals
Atopic Dermatitis
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting both children (15- 20%) and adults (2-5%). The pathogenesis of AD is complex and multifactorial, including skin barrier dysfunction and immune…
- Trial name
- NCT06983561
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05265923
- Testing
- CM310
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Keymed Biosciences Co.Ltd
Dermatitis, Atopic
China Atopic Dermatitis Registry Study
This regestry study is aimed to characterize the medical care and drug treatment under real-life conditions among Chinese patients with moderate to severe Atopic Dermatitis who are not well controlled by topical therapies.
- Trial name
- NCT05023668
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital
Hemay005, Atopic Dermatitis
A Study of Hemay005 in Adult With Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT05769946
- Testing
- Hemay005
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd